Literature DB >> 7031840

Antithrombin III concentrate: its catabolism in health and in antithrombin III deficiency.

L Tengborn, B Frohm, L E Nilsson, I M Nilsson.   

Abstract

The catabolism of purified radiolabelled antithrombin III (AT III) concentrate was studied in two normals and two patients with congenital AT III deficiency both alone and combined with warfarin. The radiolabelling with iodine monochloride did not change the quality of the concentrate. The half-life varied between 3.4 and 4.8 days. No difference between normals and patients with congenital deficiency in non-acute stage could be observed in the catabolic parameters; nor was there any influence with warfarin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7031840     DOI: 10.3109/00365518109090485

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  3 in total

1.  Pharmacokinetics of human antithrombin III concentrate in the immediate postoperative period after liver transplantation.

Authors:  Bo Rim Kim; Jaeseong Oh; Kyung-Sang Yu; Ho Geol Ryu
Journal:  Br J Clin Pharmacol       Date:  2020-02-18       Impact factor: 4.335

2.  Plasma elimination of antithrombin III (heparin cofactor activity) is accelerated in term newborn infants.

Authors:  B Schmidt; U Wais; W Pringsheim; W Künzer
Journal:  Eur J Pediatr       Date:  1984-02       Impact factor: 3.183

3.  In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomes.

Authors:  Mohammed Asmal; James B Whitney; Corinne Luedemann; Angela Carville; Robert Steen; Norman L Letvin; Ralf Geiben-Lynn
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.